Convidado
SILVIA TENEMBAUM
Head of Clinic, Department of Neurology.
National Paediatric Hospital Dr. J. P. Garrahan,
She is currently participating in five pediatric clinical studies evaluating the impact of Satralizumab and Inebilizumab in children with AQP4-IgG positive NMOSD, comparing the efficacy and safety of Ofatumumab, Siponimod, Fingolimod, and Ocrelizumab in children and adolescents with MS, and the impact of Satralizumab in pediatric patients with NMDAR encephalitis.
Atividades
